Introduction
============

Squamous cell carcinoma (SCC) and adenocarcinoma (AC) are the two most common histologic types of esophageal cancer (EC).[@b1-ott-8-137],[@b2-ott-8-137] In People's Republic of China, SCC accounts for more than 95% of EC, in contrast to the predominance of AC in the West.[@b3-ott-8-137],[@b4-ott-8-137] Although advances have occurred in comprehensive therapy, patients with EC still has a poor prognosis due to late diagnosis, rapid growth, and high recurrence rate.[@b5-ott-8-137],[@b6-ott-8-137] There are important biological differences between SCC and AC, therefore, a prognostic study that takes into account the predominance of SCC in People's Republic of China is more and more important.

It is well known that systemic inflammatory response plays an important role in cancer progression.[@b7-ott-8-137],[@b8-ott-8-137] The systemic inflammatory response, which is usually measured by peripheral blood-based parameters, such as C-reactive protein, neutrophil, lymphocyte or platelet count, has been shown to be a predictive factor in various cancers, including ECs.[@b9-ott-8-137],[@b10-ott-8-137] Moreover, lymphocyte to monocyte ratio (LMR) is another inflammatory marker. Recently studies demonstrated that LMR is associated with prognosis in several cancers, such as hematological malignancy, colon cancer, and lung cancer.[@b11-ott-8-137]--[@b13-ott-8-137] However, to the best of our knowledge, no studies regarding the predictive value of LMR in patients with EC are available. Therefore, the aim of this study was to investigate the prognostic role of LMR in patients with esophageal squamous cell carcinoma (ESCC).

Patients and methods
====================

During the period between January 2006 and December 2008, a retrospective analysis was conducted on 348 patients with ESCC who underwent surgery at Zhejiang Cancer Hospital (Hangzhou, People's Republic of China). The inclusion criteria were as follows: 1) patients with ESCC confirmed by histopathology with curative esophagectomy; 2) patients who had not received neoadjuvant chemotherapy and/or radiotherapy, and 3) preoperative blood test results were obtained within 1 week prior to surgery. Ethical approval was obtained from the Ethical Committees of Zhejiang Cancer Hospital.

All patients were treated with radical esophagectomy. Patients who had received preoperative neoadjuvant therapy (chemotherapy and/or radiotherapy) were excluded from our study. During that period, the role of postoperative adjuvant chemoradiotherapy was controversial, therefore, adjuvant therapy was not mandatory.

Data on preoperative blood cell counts were extracted from our medical records. All white blood cell and differential counts (including lymphocyte count and monocyte count) were taken within 1 week prior to surgery. In this study, the LMR was defined as the absolute lymphocyte count (ALC) divided by the absolute monocyte count (AMC).

Statistical analysis
====================

Statistical analysis was conducted with SPSS 17.0 (SPSS Inc., Chicago, IL, USA). As this series described the prognosis of patients with ESCC, a cancer-specific survival (CSS) analysis would be more appropriate. The CSS was defined as the time from surgery to cancer-related death. A receiver operating characteristic (ROC) curve for CSS prediction was plotted to verify the optimum cut-off point for LMR, ALC, and AMC. Independent Student's *t*-test was used to compare groups of continuous LMR. Chi-squared test was used to determine the significance of differences for dichotomous LMR. Pearson correlation analysis was used to determine the correlation of LMR, ALC, and AMC. The CSS was calculated by the Kaplan--Meier method, and the difference was assessed by the log-rank test. A univariate analysis was used to examine the association between various prognostic predictors and CSS. Possible prognostic factors associated with CSS were considered in a multivariable Cox proportional hazards regression analysis. A *P*-value less than 0.05 was considered to be statistically significant.

Results
=======

The baseline characteristics are shown in [Table 1](#t1-ott-8-137){ref-type="table"}. Among the 348 patients, 45 (12.9%) were women and 303 (87.1%) were men. The mean age was 59.2±7.8 years (range 38--80 years). The histograms of ALC, AMC, and LMR are shown in [Figure 1](#f1-ott-8-137){ref-type="fig"}. The mean ALC and AMC were 1.67±0.66 (×10^9^/L) and 0.70±0.41 (×10^9^/L), respectively, with a mean LMR of 3.51±3.44. There were significant positive correlations between ALC and AMC (*r*=0.345, *P*\<0.001, [Figure 2A](#f2-ott-8-137){ref-type="fig"}), ALC and LMR (*r*=0.174, *P*=0.001, [Figure 2B](#f2-ott-8-137){ref-type="fig"}). However, there were significant negative correlations between AMC and LMR (*r*=-0.490, *P*\<0.001, [Figure 2C](#f2-ott-8-137){ref-type="fig"}).

ROC curves for survival prediction (CSS) were plotted to verify the optimum cut-off points for ALC, AMC, and LMR, which were 1.75 (×10^9^/L), 0.55 (×10^9^/L), and 2.93, respectively ([Figure 3](#f3-ott-8-137){ref-type="fig"}). Based on the cut-off value of LMR, patients were then divided into two groups for further analysis (patients with LMR ≤2.93 and patients with LMR \>2.93). Overall, there were 203 (58.3%) patients with LMR ≤2.93 and 145 (41.7%) patients with LMR \>2.93. Our study showed that LMR was associated with tumor length (*P*=0.033), depth of invasion (*P*=0.015), nodal metastasis (*P*=0.007), ALC (*P*\<0.001), and AMC (*P*\<0.001) ([Table 2](#t2-ott-8-137){ref-type="table"}).

Patients with LMR ≤2.93 had a significantly worse 5-year CSS than patients with LMR \>2.93 (21.2% versus 59.3%, *P*\<0.001) ([Figure 4A](#f4-ott-8-137){ref-type="fig"}). In addition, there were also significant differences in 5-year CSS regarding ALC (52.0% versus 28.5%, *P*\<0.001, [Figure 4B](#f4-ott-8-137){ref-type="fig"}) and AMC (48.6% versus 28.9%, *P*\<0.001, [Figure 4C](#f4-ott-8-137){ref-type="fig"}). For subgroup analysis, the predictive value of LMR was significant in patients with T1-2 cancer (*P*=0.003), T3-4a (*P*\<0.001), and patients with (*P*=0.044) or without (*P*\<0.001) nodal metastasis ([Figure 5](#f5-ott-8-137){ref-type="fig"}). In addition, the predictive value of LMR was also significantly stratified by ALC (*P*\<0.001) and AMC (*P*\<0.001) ([Figure 6](#f6-ott-8-137){ref-type="fig"}).

By univariate analysis, we found that tumor length, vessel invasion, depth of invasion, nodal metastasis, ALC, AMC, and LMR had significant associations with CSS. Then multivariate Cox proportional hazards model demonstrated that LMR was an independent prognostic factor in patients with ESCC ([Table 3](#t3-ott-8-137){ref-type="table"}). LMR \>2.93 had a hazard ratio of 0.60 (95% confidence interval: 0.407--0.885, *P*=0.010) for CSS ([Table 3](#t3-ott-8-137){ref-type="table"}).

Discussion
==========

To the best of our knowledge, this is the first study to determine the prognostic value of LMR in predicting postoperative prognosis for patients with ESCC. Our study showed that LMR is associated with tumor progression and can be considered as an independent predictive marker of prognosis in patients with ESCC. We used an ROC curve for survival prediction to verify the optimal cut-off point for LMR, and concluded the value of 2.93 may be the optimum cut-off point for LMR in predicting prognosis in ESCC patients.

In our study, we analyzed the potential prognostic role of LMR in ESCC patients who had not received neoadjuvant chemoradiotherapy mainly because chemotherapy and/or radiation will have an important impact on the systemic inflammation. Several different hematological indexes have shown prognostic significance in patients with EC.[@b14-ott-8-137]--[@b16-ott-8-137] Recent studies have shown a strong link between cancer and inflammation. Several peripheral inflammatory cells, such as neutrophils, lymphocytes, and monocytes, were significantly associated with prognosis in various cancers.[@b17-ott-8-137],[@b18-ott-8-137] Hoffmann et al[@b19-ott-8-137] demonstrated that a low lymphocyte amount might be responsible for a weak, insufficient immunologic reaction. Furthermore, Evani et al[@b20-ott-8-137] showed that monocytes have a role in metastasis. Therefore, monocytes seem to promote tumor progression, in contrast to the role of lymphocytes.

In the present study, therefore, we initially evaluated the usefulness of LMR for predicting the postoperative CSS in patients with ESCC. Our study showed that LMR was associated with tumor length (*P*=0.033), depth of invasion (*P*=0.015), and nodal metastasis (*P*=0.015). This observation is in line with data from Stotz et al[@b11-ott-8-137] but is contrary to the result of Lin et al[@b13-ott-8-137] who suggested that LMR is not correlated with the above factors. Furthermore, controversy exists concerning the optimal cut-off points for LMR to predict survival. In our study, therefore, an ROC curve for CSS prediction was plotted to verify the optimum cut-off point for LMR, which was 2.93. Our study showed that patients with LMR ≤2.93 had a significantly worse 5-years CSS than patients with LMR \>2.93. In multivariate analysis, LMR was a significant predictive factor of CSS.

It may well be that the influence of LMR on the subgroup with different T grades and N stagings is important for the understanding of its role in prognosis. In the further investigation, therefore, subgroup analysis was performed. In our study, the predictive value of LMR was also significant in patients with T1-2 cancer (*P*=0.003), T3-4a (*P*\<0.001), and patients with (*P*=0.044) or without (*P*\<0.001) nodal metastasis. In addition, the predictive value of LMR was also significantly stratified by ALC (*P*\<0.001) and AMC (*P*\<0.001). From the database of 348 patients with ESCC, our results clearly demonstrated that LMR can serve as an independent predictor of long-term survival for ESCC patients.

In conclusion, our study showed that LMR is associated with tumor progression and can be considered as an independent marker of prognosis in patients with ESCC. We conclude that 2.93 may be the optimum cut-off point for LMR in predicting survival in ESCC patients. However, larger prospective studies will need to be performed to confirm these preliminary results.
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![The histograms of the ALC (**A**), AMC (**B**), and LMR (**C**).\
**Abbreviations:** ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte to monocyte ratio.](ott-8-137Fig1){#f1-ott-8-137}

![Positive correlations between ALC and AMC (**A**), ALC and LMR (**B**). Negative correlation between AMC and LMR (**C**).\
**Abbreviations:** ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte to monocyte ratio.](ott-8-137Fig2){#f2-ott-8-137}

![ROC curves for survival prediction (CSS) were plotted to verify the optimum cut-off points for ALC (**A**), AMC (**B**), and LMR (**C**).\
**Abbreviations:** ROC, receiver operating characteristic; CSS, cancer-specific survival; ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte to monocyte ratio.\
**Notes:** Reference line (green); ROC line (blue).](ott-8-137Fig3){#f3-ott-8-137}

![Kaplan--Meier CSS curves stratified by LMR (**A**), ALC (**B**), and AMC (**C**).\
**Abbreviations:** CSS, cancer-specific survival; ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte to monocyte ratio; M, months.](ott-8-137Fig4){#f4-ott-8-137}

###### 

Kaplan--Meier CSS curves stratified by LMR in patients with T1-2 (**A**), T3-4a (**B**), and patients without (**C**) and with (**D**) nodal metastasis.

**Abbreviations:** CSS, cancer-specific survival; LMR, lymphocyte to monocyte ratio; M, months.
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![Kaplan--Meier CSS curves stratified by LMR in patients with ALC ≤1.75 (**A**), ALC \>1.75 (**B**), AMC ≤0.55 (**C**), and AMC \>0.55 (**D**).\
**Abbreviations:** CSS, cancer-specific survival; ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte to monocyte ratio; M, months.](ott-8-137Fig6){#f6-ott-8-137}

###### 

The baseline characteristics in patients with ESCC

                                 Cases (n, %)
  ------------------------------ --------------
  Age (mean ± SD, years)         59.2±7.8
   ≤60                           198 (56.9)
   \>60                          150 (43.1)
  Sex                            
   Female                        45 (12.9)
   Male                          303 (87.1)
  Tumor length (mean ± SD, cm)   4.35±1.85
   ≤3.0                          92 (26.4)
   \>3.0                         256 (73.6)
  Tumor location                 
   Upper                         18 (5.2)
   Middle                        168 (48.3)
   Lower                         162 (46.5)
  Differentiation                
   Well                          50 (14.4)
   Moderate                      225 (64.7)
   Poor                          73 (20.9)
  Depth of invasion              
   T1                            60 (17.2)
   T2                            54 (15.5)
   T3                            196 (56.3)
   T4a                           38 (11.0)
  Nodal metastasis               
   Negative                      179 (51.4)
   Positive                      169 (48.6)
  ALC (mean ± SD, ×10^9^/L)      1.67±0.66
  AMC (mean ± SD, ×10^9^/L)      0.70±0.41
  LMR (mean ± SD)                3.51±3.44

**Abbreviations:** ESCC, esophageal squamous cell carcinoma; SD, standard deviation; ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte to monocyte ratio.

###### 

Comparison of baseline clinical characteristics based on LMR

                      Cases (n, %)   LMR ≤2.93 (n, %)   LMR \>2.93 (n, %)   *P*-value
  ------------------- -------------- ------------------ ------------------- -----------
  Age (years)                                                               0.583
   ≤60                198 (56.9)     113 (55.7)         85 (58.6)           
   \>60               150 (43.1)     90 (44.3)          60 (41.4)           
  Sex                                                                       0.168
   Female             45 (12.9)      22 (10.8)          23 (15.9)           
   Male               303 (87.1)     181 (89.2)         122 (84.1)          
  Tumor length (cm)                                                         0.033
   ≤3                 92 (26.4)      45 (22.2)          47 (32.4)           
   \>3                256 (73.6)     158 (77.8)         98 (67.6)           
  Tumor location                                                            0.207
   Upper              18 (5.2)       12 (5.9)           6 (4.1)             
   Middle             168 (48.3)     90 (44.3)          78 (53.8)           
   Lower              162 (46.5)     101 (49.8)         61 (42.1)           
  Vessel invasion                                                           0.200
   Negative           292 (83.9)     166 (81.8)         126 (86.9)          
   Positive           56 (16.1)      37 (18.2)          19 (13.1)           
  Differentiation                                                           0.809
   Well               50 (14.4)      29 (14.3)          21 (14.5)           
   Moderate           225 (64.7)     129 (63.5)         96 (66.2)           
   Poor               73 (20.9)      45 (22.2)          28 (19.3)           
  Depth of invasion                                                         0.015
   T1-2               114 (32.8)     56 (27.6)          58 (40.0)           
   T3-4a              234 (67.5)     147 (72.4)         87 (60.0)           
  Nodal metastasis                                                          0.007
   Negative           179 (51.4)     92 (45.3)          87 (60.0)           
   Positive           169 (48.6)     111 (54.7)         58 (40.0)           
  Adjuvant therapy                                                          0.953
   No                 243 (69.8)     142 (70.0)         101 (69.7)          
   Yes                105 (30.2)     61 (30.0)          44 (30.3)           
  ALC (×10^9^/L)                                                            \<0.001
   ≤1.75              221 (63.5)     149 (73.4)         72 (49.7)           
   \>1.75             127 (36.5)     54 (26.6)          73 (50.3)           
  AMC (×10^9^/L)                                                            \<0.001
   ≤0.55              144 (41.4)     36 (17.7)          108 (74.5)          
   \>0.55             204 (58.6)     167 (82.3)         37 (25.5)           

**Abbreviations:** ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte to monocyte ratio.

###### 

Univariate and multivariate analyses of CSS in ESCC patients

                      Univariate analysis    *P*-value   Multivariate analysis   *P*-value
  ------------------- ---------------------- ----------- ----------------------- -----------
  Age (years)                                0.720       --                      --
   ≤60                1.000                                                      
   \>60               1.050 (0.804--1.372)                                       
  Sex                                        0.676       --                      --
   Female             1.000                                                      
   Male               1.090 (0.728--1.630)                                       
  Tumor length (cm)                          \<0.001                             0.415
   ≤3                 1.000                              1.000                   
   \>3                1.921 (1.377--2.678)               1.167 (0.805--1.690)    
  Tumor location                             0.327       --                      --
   Upper/middle       1.000                                                      
   Lower              1.142 (0.876--1.488)                                       
  Vessel invasion                            \<0.001                             0.190
   Negative           1.000                              1.000                   
   Positive           1.909 (1.376--2.647)               1.262 (0.891--1.789)    
  Differentiation                            0.071       --                      --
   Well/moderate      1.000                                                      
   Poor               1.341 (0.976--1.844)                                       
  Depth of invasion                          \<0.001                             0.034
   T1-2               1.000                              1.000                   
   T3-4a              2.158 (1.573--2.960)               1.475 (1.030--2.113)    
  Nodal metastasis                           \<0.001                             \<0.001
   Negative           1.000                              1.000                   
   Positive           2.920 (2.208--3.862)               2.156 (1.588--2.929)    
  Adjuvant therapy                           0.403       --                      --
   No                 1.000                                                      
   Yes                1.130 (0.849--1.506)                                       
  ALC (×10^9^/L)                             \<0.001                             0.006
   ≤1.75              1.000                              1.000                   
   \>1.75             0.570 (0.424--0.767)               0.628 (0.450--0.878)    
  AMC (×10^9^/L)                             0.001                               0.173
   ≤0.55              1.000                              1.000                   
   \>0.55             1.641 (1.239--2.173)               1.282 (0.897--1.832)    
  LMR                                        \<0.001                             0.010
   ≤2.93              1.000                              1.000                   
   \>2.93             0.394 (0.292--0.532)               0.600 (0.407--0.885)    

**Abbreviations:** CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval; ESCC, esophageal squamous cell carcinoma; ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte to monocyte ratio.
